Clinical Trials Logo
  1. Home
  2. Premenopausal Breast Cancer
  3. NCT02990845

Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer — PEER  

Premenopausal Breast Cancer Clinical Trial

Official title:
A Pilot Study of Pembrolizumab and Exemestane/ Leuprolide in Premenopausal Hormone Receptor Positive/ HER2 Negative Locally Advanced or Metastatic Breast Cancer

Clinical Trial Summary

This is an open-label, single-arm, multicenter, pilot study of pembrolizumab, exemestane, and leuprolide for subjects being resistant for front-line hormonal therapy for inoperable locally advanced or metastatic hormonal receptor positive (HR+)/ Human epidermal growth factor receptor 2 (HER2) negative breast cancer. All the patients will be included in the final tolerability and preliminary efficacy analysis. The efficacy objectives including PFS, overall response rate (ORR), clinical benefit rate (CBR), and duration of response (DOR). Adverse effects will be recorded according to CTCAE v4.0.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02990845
Study type Interventional
Source National Taiwan University Hospital
Contact
Status Terminated
Phase Phase 1/Phase 2
Start date September 15, 2017
Completion date August 16, 2022
View Details
See also
  Status Clinical Trial Phase
Terminated NCT01726322 - Ovarian Reserve in Premenopausal Breast Cancer
Recruiting NCT05982093 - Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer Phase 2
Active, not recruiting NCT04997941 - Higher Dose Preoperative taMOxifen in Premenopausal bREast Cancer Patients Phase 2
Recruiting NCT06458764 - Sexual Dysfunction Check-up in Premenopausal Breast Cancer Survivors Taking Endocrine Therapy: A Cross-Sectional Study
Completed NCT03209518 - Special Drug Use Surveillance of Leuprorelin for Injection Kit 22.5 mg in "Premenopausal Breast Cancer"
Not yet recruiting NCT05801705 - Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study
Active, not recruiting NCT03407768 - Role of Individualized Intervention(s) in Hormone-Receptor Positive Early-stage Breast Cancer N/A
Recruiting NCT05720260 - Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC Phase 2
Recruiting NCT05333328 - OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk Phase 4
Not yet recruiting NCT06225284 - Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients Phase 2
Completed NCT01546649 - A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-naïve Patients With Premenopausal Breast Cancer Phase 3